Open Access

Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets

  • Authors:
    • Shuhui Chen
    • Elisa Cavazza
    • Catherine Barlier
    • Julia Salleron
    • Pierre Filhine‑Tresarrieu
    • Céline Gavoille
    • Jean‑Louis Merlin
    • Alexandre Harlé
  • View Affiliations

  • Published online on: September 2, 2016     https://doi.org/10.3892/ol.2016.5083
  • Pages: 3264-3272
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite great histological and molecular heterogeneity, the clinical management of high‑grade ovarian carcinomas remains unspecialized. As a major subgroup, high-grade serous ovarian carcinomas (HGSOCs) require novel therapies. In addition to utilizing conventional histological prognostic markers and performing oncogenetic investigations, the molecular diagnostic method of next generation sequencing (NGS) was performed to identify ‘druggable’ targets that could provide access to innovative therapy. The present study was performed in 45 HGSOC patients (mean age, 59.1 years; range, 25‑87 years) with histologically proven HGSOC. Breast cancer 1/2 (BRCA1/2) germline mutations were screened in 17 patients with a familial or personal history of cancer, which was justified by oncogenetic investigations. Tumor protein 53 (P53) and phosphatase and tensin homolog (PTEN) expression were assessed in formalin‑fixed paraffin‑embedded tissues using immunohistochemistry. Somatic mutations of Kirsten rat sarcoma viral oncogene homolog, neuroblastoma RAS viral oncogene homolog (NRAS), B‑Raf proto‑oncogene, serine/threonine kinase, phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit α (PIK3CA) and MET proto‑oncogene, receptor tyrosine kinase (MET) were screened using NGS on DNA extracts from frozen tumor specimens obtained at diagnosis. With a median follow‑up of 38 months (range, 6-93 months), 20 patients are alive, 10 patients are disease‑free and 14 patients progressed within 6 months following platinum‑based therapy. P53 overexpression was detected in 67% of patients and PTEN loss was detected in 38% of the patients. The overexpression of mutant P53 was found to be associated with a longer progression‑free and overall survival. In total, 2 NRAS (exon 3), 3 PIK3CA (exon 5 and 10) and 5 MET mutations (exons 14 and 18) were detected. In HGSOCs, in addition to P53 and PTEN alterations, somatic genetic abnormalities can be detected using NGS and provide molecular rationale for targeted therapies, potentially offering novel therapeutic opportunities to patients.
View Figures
View References

Related Articles

Journal Cover

November 2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Chen, S., Cavazza, E., Barlier, C., Salleron, J., Filhine‑Tresarrieu, P., Gavoille, C. ... Harlé, A. (2016). Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets. Oncology Letters, 12, 3264-3272. https://doi.org/10.3892/ol.2016.5083
MLA
Chen, S., Cavazza, E., Barlier, C., Salleron, J., Filhine‑Tresarrieu, P., Gavoille, C., Merlin, J., Harlé, A."Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets". Oncology Letters 12.5 (2016): 3264-3272.
Chicago
Chen, S., Cavazza, E., Barlier, C., Salleron, J., Filhine‑Tresarrieu, P., Gavoille, C., Merlin, J., Harlé, A."Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets". Oncology Letters 12, no. 5 (2016): 3264-3272. https://doi.org/10.3892/ol.2016.5083